Low-dose Tolvaptan for Inpatient Hyponatraemia.
Condition(s):Hyponatremia; SIADHLast Updated:March 8, 2024Recruiting
Include Studies Not Open or Pending
Condition(s):Hyponatremia; SIADHLast Updated:March 8, 2024Recruiting
Condition(s):Autosomal Recessive Polycystic Kidney (ARPKD)Last Updated:November 1, 2023Recruiting
Condition(s):Autosomal Recessive Polycystic Kidney Disease (ARPKD)Last Updated:September 15, 2023Recruiting
Condition(s):Pulmonary Arterial Hypertension; Randomized Controlled TrialLast Updated:October 6, 2022Recruiting
Condition(s):SafetyLast Updated:September 28, 2023Recruiting
Condition(s):Antidiuretic Hormone, Inappropriate SecretionLast Updated:November 2, 2023Recruiting
Condition(s):Autosomal Dominant Polycystic Kidney Disease; Nephrogenic Diabetes Insipidus; Acquired Nephrogenic Diabetes Insipidus; Congenital Nephrogenic Diabetes InsipidusLast Updated:January 19, 2023Recruiting
Condition(s):ADPKD (Autosomal Dominant Polycystic Kidney Disease)Last Updated:August 7, 2023Recruiting
Condition(s):Autosomal Dominant Polycystic Kidney Disease (ADPKD)Last Updated:February 12, 2024Recruiting
Condition(s):Heart FailureLast Updated:March 10, 2023Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.